Table 1.
Patient demographics and baseline characteristics.
| Isa (N = 21) | |
|---|---|
| Age, median (range), yrs | 58 (46–72) |
| < 65 years, n (%) | 18 (85.7) |
| 65 to < 75 years, n (%) | 3 (14.3) |
| Female, n (%) | 11 (52.4) |
| Male, n (%) | 10 (47.6) |
| ECOG PS, n (%) | |
| 0 | 6 (28.6) |
| 1 | 12 (57.1) |
| 2 | 3 (14.3) |
| Median time from initial diagnosis (range), yrs | 2.61 (0.7–10.9) |
| ISS stage at study entry, n (%) | |
| Stage I | 4 (19.0) |
| Stage II | 7 (33.3) |
| Stage III | 9 (42.9) |
| Not known | 1 (4.8) |
| Median BMPC (range) at study entry, % | 24.0 (0–97.0) |
| Patients with bone lesions at study entry, n (%) | 16 (76.2) |
| Number of prior lines, median (range) | 4 (2–11) |
| Number of prior lines, n (%) | |
| 1 | 0 |
| 2 | 7 (33.3) |
| 3 | 2 (9.5) |
| ≥ 4 | 12 (57.1) |
| Refractory to, n (%) | |
| IMiD | 19 (90.5) |
| PI | 14 (66.7) |
| IMiD and PI | 12 (57.1) |
| Refractory to last treatment regimen, n (%) | 20 (95.2) |
BMPC, bone marrow plasma cells; ECOG PS, Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory drug; Isa, isatuximab; ISS, international staging system; PI, proteasome inhibitor.